Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-02-20 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于部分持股5%以上股东减持公司股份计划的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a plan by a shareholder holding more than 5% of the company's shares to reduce their holdings. It details the shareholder's identity, the number and percentage of shares to be reduced, the methods and timing of the reduction, and compliance with relevant securities laws and regulations. There is no financial data, earnings information, or report attached or referenced as being published. The document is a regulatory announcement about a significant shareholder's planned share reduction, which fits the category of Major Shareholding Notification (MRQ). The document length is short (1491 characters), and it is not a report or a certification but a formal announcement of shareholding changes.
2023-02-20 Chinese
关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of senior management personnel at the company Haise Medical Group Co., Ltd. It details the appointment of two individuals as vice general managers, their qualifications, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or meetings. The content clearly fits the category of management information announcements, specifically about changes in senior management.
2023-02-14 Chinese
独立董事对相关事项发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment of senior management personnel. It references compliance with company law and stock exchange regulations, and it specifically addresses the approval of appointments to senior management. This type of document is related to board or management changes rather than a full report or announcement of financial results. The document length is short and focused on management appointments, fitting the category of Board/Management Information (MANG).
2023-02-14 Chinese
第四届董事会第四十五次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of a board meeting resolution regarding the appointment of senior management personnel. It mentions the board meeting date, voting results, and appointment details of new vice general managers. There is no financial data or report content, only a formal announcement of management changes. This fits the category of Board/Management Information (MANG). The document length is short and focused on management appointments, confirming the classification.
2023-02-14 Chinese
关于终止实施首期限制性股票激励计划并回购注销相关限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the termination of its first restricted stock incentive plan and the repurchase and cancellation of related restricted shares. It details the background, reasons, and effects of this termination and repurchase, including board and supervisory approvals, independent director opinions, and legal opinions. The content focuses on changes in the company's capital structure due to share repurchase and cancellation related to stock incentives. There are no financial statements or comprehensive financial performance data presented, nor is this a report of earnings or management discussion of results. The document is a formal announcement about a capital change event (repurchase and cancellation of shares) related to stock incentives. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2023-02-10 Chinese
海思科医药集团股份有限公司以自筹资金预先投入募集资金投资项目情况鉴证报告
Regulatory Filings
2023-02-10 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.